Stock info Virbac | Filter  Basic-Info

Virbac

The past year yielded positive returns for Virbac investors

The stock lost over the past 12 months at around 17 percent. The period between August 2011 and August 2016 was a profitable period for the investors. The stock rose on average 37 percent. Virbac's revenues between 2011 and 2015 were very constant and moved between 695,16 million euros and 852,62 million euros. Virbac's net results between 2011 and 2015 were quite unstable and moved between 58,53 million euros and 13,45 million euros.

Virbac's core business is the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent over the period 2006-2016. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

Over the past 5 years the French company paid out dividends. On average Virbac's dividend yield over the past 5 years was around 7,45 percent annually.

Virbac' balance mostly consists of equity

Last year the balance sheet of the French company was worth 1,43 billion euros. The total debt was around 992,14 million euros. This is 69,35 percent of the total balance sheet.

At the end of 2015 the French company had around 8,43 million stocks listed.

All of Virbac's annual reports are stored here. More information about Virbac can be found it's website. .